These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32452526)

  • 1. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
    Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
    Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 3. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
    Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
    Okahashi N; Uchihara M; Hoshino E
    Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
    Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
    Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
    Du S; Fu DB; A Bota D; Kong XT
    CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
    Kallam A; Hansen N; Bierman P
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
    Chamoun K; Choquet S; Boyle E; Houillier C; Larrieu-Ciron D; Al Jijakli A; Delrieu V; Delwail V; Morschhauser F; Hoang-Xuan K; Soussain C
    Neurology; 2017 Jan; 88(1):101-102. PubMed ID: 27864520
    [No Abstract]   [Full Text] [Related]  

  • 12. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
    Wang L; Li X; He YZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
    Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
    [No Abstract]   [Full Text] [Related]  

  • 14. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
    Yi JH; Kim SJ; Yoon DH; Suh C; Chang MH; Yang DH; Jo JC; Hyun SY; Eom HS; Lee JO; Kwon JH; Han SH; Lee SS; Kwak JY; Kim SH; Kim DS; Lee JH; Oh SY; Ryoo HM; Kim HJ; Kim WS
    Cancer Commun (Lond); 2021 Mar; 41(3):275-278. PubMed ID: 33626235
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Tanigawa T; Sakurai M; Kato J; Mizuno K; Fujita S; Koda Y; Kikuchi T; Shimizu T; Okamoto S; Kataoka K
    Ann Hematol; 2022 Mar; 101(3):723-724. PubMed ID: 34235557
    [No Abstract]   [Full Text] [Related]  

  • 18. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
    Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S
    J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Qualls D; Lam HY; Whiting K; Kumar A; Matasar M; Owens C; Nichols C; Espeleta JA; Qiu A; Subzwari S; Biggar E; Seshan V; Salles G; Younes A; Batlevi C
    Blood Adv; 2022 Sep; 6(18):5262-5266. PubMed ID: 35171976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.